Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Epidemiology and pathogenesis of Neisseria gonorrhoeae infection

Gregory A Price, PhD
Margaret C Bash, MD, MPH
Section Editor
Noreen A Hynes, MD, MPH, DTM&H
Deputy Editor
Allyson Bloom, MD


Infection with Neisseria gonorrhoeae is a global problem. In the United States, it is the second most commonly reported communicable disease and the second most prevalent sexually transmitted infection (STI). Symptomatic gonorrhea results in urethritis in males and cervicitis in females. Untreated gonorrhea can lead to epididymitis in males and pelvic inflammatory disease (PID) in females, which can lead to serious sequelae such as infertility, ectopic pregnancy, and chronic pelvic pain [1]. Infrequently, gonococcal infections can become invasive, leading to disseminated gonococcal infections (DGI), which may result in gonococcal arthritis-dermatitis syndrome, suppurative arthritis, endocarditis, and meningitis.

The epidemiology and pathogenesis of gonorrhea will be discussed here. The clinical manifestations, diagnosis, and management of gonococcal infections are discussed in detail elsewhere. (See "Clinical manifestations and diagnosis of Neisseria gonorrhoeae infection in adults and adolescents" and "Cutaneous manifestations of gonorrhea" and "Treatment of uncomplicated gonococcal infections" and "Disseminated gonococcal infection".)


Global incidence — The precise global burden of N. gonorrhoeae is difficult to establish because of the lack of diagnostic capability and/or reporting systems in many parts of the world. The World Health Organization (WHO) has estimated the global incidence of several sexually transmitted infections (STIs) among individuals aged 15 to 49 years based on data from regions that have good case-based surveillance systems as well as data from population-based studies [2]. In 2008, the WHO estimated global incidence of N. gonorrhoeae was 106 million cases, which represented a 21 percent increase over the estimate for 2005. The highest incidence areas included Africa and the Western Pacific (including China and Australia) regions. In one review of infections during pregnancy in sub-Saharan Africa, the prevalence of sexually transmitted and reproductive tract infections was comparable with that of malaria [3]. The prevalence of N. gonorrhoeae during pregnancy ranged from 1.5 percent in West and Central Africa to 4.9 percent in East and Southern Africa.

There are several potential reasons for the increasing global rates of gonorrhea. As an example, in some areas, particularly sub-Saharan Africa, incidence rates of gonorrhea may be influenced by the increased prevalence of HIV infection (see 'Association with HIV' below). Improved diagnostics and increased reporting from certain countries also likely contribute.

United States

Incidence — Gonorrhea is the second most commonly reported communicable disease and the second most prevalent sexually transmitted infection (STI) in the United States. In 2015, there were 395,216 cases of gonorrhea reported in the US [1]. However, the actual number of cases is likely much higher due to under-reporting and asymptomatic infections [4,5].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 16, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2015. Atlanta, GA: US Department of Health and Human Services; October 2016.
  2. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/ (Accessed on February 18, 2015).
  3. Chico RM, Mayaud P, Ariti C, et al. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA 2012; 307:2079.
  4. American Social Health Association. Sexually transmitted diseasesin America: how many cases and at what cost? Menlo Park, CA: Kaiser Family Foundation, 1998.
  5. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40:187.
  6. Toomey KE, Moran JS, Rafferty MP, Beckett GA. Epidemiological considerations of sexually transmitted diseases in underserved populations. Infect Dis Clin North Am 1993; 7:739.
  7. Fox KK, Whittington WL, Levine WC, et al. Gonorrhea in the United States, 1981-1996. Demographic and geographic trends. Sex Transm Dis 1998; 25:386.
  8. Handsfield HH. Decreasing incidence of gonorrhea in homosexually active men--minimal effect on risk of AIDS. West J Med 1985; 143:469.
  9. Moran JS, Janes HR, Peterman TA, Stone KM. Increase in condom sales following AIDS education and publicity, United States. Am J Public Health 1990; 80:607.
  10. Fox KK, del Rio C, Holmes KK, et al. Gonorrhea in the HIV era: a reversal in trends among men who have sex with men. Am J Public Health 2001; 91:959.
  11. Stall RD, Hays RB, Waldo CR, et al. The Gay '90s: a review of research in the 1990s on sexual behavior and HIV risk among men who have sex with men. AIDS 2000; 14 Suppl 3:S101.
  12. Hook EW 3rd, Reichart CA, Upchurch DM, et al. Comparative behavioral epidemiology of gonococcal and chlamydial infections among patients attending a Baltimore, Maryland, sexually transmitted disease clinic. Am J Epidemiol 1992; 136:662.
  13. Mertz KJ, Levine WC, Mosure DJ, et al. Screening women for gonorrhea: demographic screening criteria for general clinical use. Am J Public Health 1997; 87:1535.
  14. Klausner JD, Barrett DC, Dithmer D, et al. Risk factors for repeated gonococcal infections: San Francisco, 1990-1992. J Infect Dis 1998; 177:1766.
  15. Ellen JM, Hessol NA, Kohn RP, Bolan GA. An investigation of geographic clustering of repeat cases of gonorrhea and chlamydial infection in San Francisco, 1989-1993: evidence for core groups. J Infect Dis 1997; 175:1519.
  16. Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983; 250:3205.
  17. Lin JS, Donegan SP, Heeren TC, et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis 1998; 178:1707.
  18. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS 1993; 7:95.
  19. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349:1868.
  20. McClelland RS, Lavreys L, Katingima C, et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis 2005; 191:333.
  21. Malott RJ, Keller BO, Gaudet RG, et al. Neisseria gonorrhoeae-derived heptose elicits an innate immune response and drives HIV-1 expression. Proc Natl Acad Sci U S A 2013; 110:10234.
  22. Sheung A, Rebbapragada A, Shin LY, et al. Mucosal Neisseria gonorrhoeae coinfection during HIV acquisition is associated with enhanced systemic HIV-specific CD8 T-cell responses. AIDS 2008; 22:1729.
  23. Unemo M, Olcén P, Albert J, Fredlund H. Comparison of serologic and genetic porB-based typing of Neisseria gonorrhoeae: consequences for future characterization. J Clin Microbiol 2003; 41:4141.
  24. Hook EW 3rd, Judson FN, Handsfield HH, et al. Auxotype/serovar diversity and antimicrobial resistance of Neisseria gonorrhoeae in two mid-sized American cities. Sex Transm Dis 1987; 14:141.
  25. Kilmarx PH, Knapp JS, Xia M, et al. Intercity spread of gonococci with decreased susceptibility to fluoroquinolones: a unique focus in the United States. J Infect Dis 1998; 177:677.
  26. O'Rourke M, Ison CA, Renton AM, Spratt BG. Opa-typing: a high-resolution tool for studying the epidemiology of gonorrhoea. Mol Microbiol 1995; 17:865.
  27. Ward H, Ison CA, Day SE, et al. A prospective social and molecular investigation of gonococcal transmission. Lancet 2000; 356:1812.
  28. Heymans R, A Matser A, Bruisten SM, et al. Distinct Neisseria gonorrhoeae transmission networks among men who have sex with men in Amsterdam, The Netherlands. J Infect Dis 2012; 206:596.
  29. Unemo M, Dillon JA. Review and international recommendation of methods for typing neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology. Clin Microbiol Rev 2011; 24:447.
  30. Martin IM, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189:1497.
  31. Bennett JS, Jolley KA, Sparling PF, et al. Species status of Neisseria gonorrhoeae: evolutionary and epidemiological inferences from multilocus sequence typing. BMC Biol 2007; 5:35.
  32. Demczuk W, Lynch T, Martin I, et al. Whole-genome phylogenomic heterogeneity of Neisseria gonorrhoeae isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. J Clin Microbiol 2015; 53:191.
  33. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88:6.
  34. Centers for Disease Control and Prevention (CDC). Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011; 60:873.
  35. European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe - 2010. ECDC, Stockholm, 2012.
  36. Ray K, Bala M, Kumari S, Narain JP. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex Transm Dis 2005; 32:178.
  37. Australian Gonococcal Surveillance Programme annual reports. http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-annlrpt-gonoanrep.htm (Accessed on November 01, 2014).
  38. Vandepitte J, Hughes P, Matovu G, et al. High prevalence of ciprofloxacin-resistant gonorrhea among female sex workers in Kampala, Uganda (2008-2009). Sex Transm Dis 2014; 41:233.
  39. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401.
  40. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538.
  41. Chan CH, McCabe CJ, Fisman DN. Core groups, antimicrobial resistance and rebound in gonorrhoea in North America. Sex Transm Infect 2012; 88:200.
  42. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N gonorrhoeae. Sex Transm Infect 2013; 89 Suppl 4:iv47.
  43. Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013; 158:321.
  44. Sparling PF. Genetic transformation of Neisseria gonorrhoeae to streptomycin resistance. J Bacteriol 1966; 92:1364.
  45. Stohl EA, Dale EM, Criss AK, Seifert HS. Neisseria gonorrhoeae metalloprotease NGO1686 is required for full piliation, and piliation is required for resistance to H2O2- and neutrophil-mediated killing. MBio 2013; 4.
  46. Swanson J. Studies on gonococcus infection. IV. Pili: their role in attachment of gonococci to tissue culture cells. J Exp Med 1973; 137:571.
  47. Wolfgang M, Lauer P, Park HS, et al. PilT mutations lead to simultaneous defects in competence for natural transformation and twitching motility in piliated Neisseria gonorrhoeae. Mol Microbiol 1998; 29:321.
  48. Seifert HS, Ajioka RS, Marchal C, et al. DNA transformation leads to pilin antigenic variation in Neisseria gonorrhoeae. Nature 1988; 336:392.
  49. Rothbard JB, Fernandez R, Wang L, et al. Antibodies to peptides corresponding to a conserved sequence of gonococcal pilins block bacterial adhesion. Proc Natl Acad Sci U S A 1985; 82:915.
  50. Criss AK, Kline KA, Seifert HS. The frequency and rate of pilin antigenic variation in Neisseria gonorrhoeae. Mol Microbiol 2005; 58:510.
  51. Hill SA, Davies JK. Pilin gene variation in Neisseria gonorrhoeae: reassessing the old paradigms. FEMS Microbiol Rev 2009; 33:521.
  52. Boslego JW, Tramont EC, Chung RC, et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 1991; 9:154.
  53. Rudel T, Scheurerpflug I, Meyer TF. Neisseria PilC protein identified as type-4 pilus tip-located adhesin. Nature 1995; 373:357.
  54. Rahman M, Källström H, Normark S, Jonsson AB. PilC of pathogenic Neisseria is associated with the bacterial cell surface. Mol Microbiol 1997; 25:11.
  55. Rudel T, Boxberger HJ, Meyer TF. Pilus biogenesis and epithelial cell adherence of Neisseria gonorrhoeae pilC double knock-out mutants. Mol Microbiol 1995; 17:1057.
  56. Scheuerpflug I, Rudel T, Ryll R, et al. Roles of PilC and PilE proteins in pilus-mediated adherence of Neisseria gonorrhoeae and Neisseria meningitidis to human erythrocytes and endothelial and epithelial cells. Infect Immun 1999; 67:834.
  57. Källström H, Blackmer Gill D, Albiger B, et al. Attachment of Neisseria gonorrhoeae to the cellular pilus receptor CD46: identification of domains important for bacterial adherence. Cell Microbiol 2001; 3:133.
  58. Källström H, Liszewski MK, Atkinson JP, Jonsson AB. Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol 1997; 25:639.
  59. Kirchner M, Heuer D, Meyer TF. CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. Infect Immun 2005; 73:3072.
  60. Tobiason DM, Seifert HS. Inverse relationship between pilus-mediated gonococcal adherence and surface expression of the pilus receptor, CD46. Microbiology 2001; 147:2333.
  61. Morand PC, Bille E, Morelle S, et al. Type IV pilus retraction in pathogenic Neisseria is regulated by the PilC proteins. EMBO J 2004; 23:2009.
  62. Rudel T, Facius D, Barten R, et al. Role of pili and the phase-variable PilC protein in natural competence for transformation of Neisseria gonorrhoeae. Proc Natl Acad Sci U S A 1995; 92:7986.
  63. Swanson J, Barrera O, Sola J, Boslego J. Expression of outer membrane protein II by gonococci in experimental gonorrhea. J Exp Med 1988; 168:2121.
  64. Sadarangani M, Pollard AJ, Gray-Owen SD. Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev 2011; 35:498.
  65. Jerse AE, Cohen MS, Drown PM, et al. Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. J Exp Med 1994; 179:911.
  66. Stern A, Brown M, Nickel P, Meyer TF. Opacity genes in Neisseria gonorrhoeae: control of phase and antigenic variation. Cell 1986; 47:61.
  67. Virji M, Watt SM, Barker S, et al. The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Mol Microbiol 1996; 22:929.
  68. Bos MP, Grunert F, Belland RJ. Differential recognition of members of the carcinoembryonic antigen family by Opa variants of Neisseria gonorrhoeae. Infect Immun 1997; 65:2353.
  69. Chen T, Belland RJ, Wilson J, Swanson J. Adherence of pilus- Opa+ gonococci to epithelial cells in vitro involves heparan sulfate. J Exp Med 1995; 182:511.
  70. van Putten JP, Paul SM. Binding of syndecan-like cell surface proteoglycan receptors is required for Neisseria gonorrhoeae entry into human mucosal cells. EMBO J 1995; 14:2144.
  71. Young JD, Blake M, Mauro A, Cohn ZA. Properties of the major outer membrane protein from Neisseria gonorrhoeae incorporated into model lipid membranes. Proc Natl Acad Sci U S A 1983; 80:3831.
  72. Fudyk TC, Maclean IW, Simonsen JN, et al. Genetic diversity and mosaicism at the por locus of Neisseria gonorrhoeae. J Bacteriol 1999; 181:5591.
  73. van Putten JP, Duensing TD, Carlson J. Gonococcal invasion of epithelial cells driven by P.IA, a bacterial ion channel with GTP binding properties. J Exp Med 1998; 188:941.
  74. Edwards JL, Butler EK. The Pathobiology of Neisseria gonorrhoeae Lower Female Genital Tract Infection. Front Microbiol 2011; 2:102.
  75. Harvey HA, Jennings MP, Campbell CA, et al. Receptor-mediated endocytosis of Neisseria gonorrhoeae into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor. Mol Microbiol 2001; 42:659.
  76. Harvey HA, Porat N, Campbell CA, et al. Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm. Mol Microbiol 2000; 36:1059.
  77. Porat N, Apicella MA, Blake MS. Neisseria gonorrhoeae utilizes and enhances the biosynthesis of the asialoglycoprotein receptor expressed on the surface of the hepatic HepG2 cell line. Infect Immun 1995; 63:1498.
  78. Spence JM, Clark VL. Role of ribosomal protein L12 in gonococcal invasion of Hec1B cells. Infect Immun 2000; 68:5002.
  79. Tsampalas M, Gridelet V, Berndt S, et al. Human chorionic gonadotropin: a hormone with immunological and angiogenic properties. J Reprod Immunol 2010; 85:93.
  80. Spence JM, Chen JC, Clark VL. A proposed role for the lutropin receptor in contact-inducible gonococcal invasion of Hec1B cells. Infect Immun 1997; 65:3736.
  81. Nolan GH, Osborne N. Gonococcal infections in the female. Obstet Gynecol 1973; 42:156.
  82. Rice PA. Gonococcal arthritis (disseminated gonococcal infection). Infect Dis Clin North Am 2005; 19:853.
  83. Lei ZM, Reshef E, Rao V. The expression of human chorionic gonadotropin/luteinizing hormone receptors in human endometrial and myometrial blood vessels. J Clin Endocrinol Metab 1992; 75:651.
  84. Reshef E, Lei ZM, Rao CV, et al. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990; 70:421.
  85. Serino L, Nesta B, Leuzzi R, et al. Identification of a new OmpA-like protein in Neisseria gonorrhoeae involved in the binding to human epithelial cells and in vivo colonization. Mol Microbiol 2007; 64:1391.
  86. McGee ZA, Johnson AP, Taylor-Robinson D. Pathogenic mechanisms of Neisseria gonorrhoeae: observations on damage to human fallopian tubes in organ culture by gonococci of colony type 1 or type 4. J Infect Dis 1981; 143:413.
  87. McGee ZA, Stephens DS, Hoffman LH, et al. Mechanisms of mucosal invasion by pathogenic Neisseria. Rev Infect Dis 1983; 5 Suppl 4:S708.
  88. Edwards JL, Apicella MA. I-domain-containing integrins serve as pilus receptors for Neisseria gonorrhoeae adherence to human epithelial cells. Cell Microbiol 2005; 7:1197.
  89. Apicella MA, Ketterer M, Lee FK, et al. The pathogenesis of gonococcal urethritis in men: confocal and immunoelectron microscopic analysis of urethral exudates from men infected with Neisseria gonorrhoeae. J Infect Dis 1996; 173:636.
  90. Giardina PC, Williams R, Lubaroff D, Apicella MA. Neisseria gonorrhoeae induces focal polymerization of actin in primary human urethral epithelium. Infect Immun 1998; 66:3416.
  91. Harvey HA, Ketterer MR, Preston A, et al. Ultrastructural analysis of primary human urethral epithelial cell cultures infected with Neisseria gonorrhoeae. Infect Immun 1997; 65:2420.
  92. Edwards JL, Brown EJ, Uk-Nham S, et al. A co-operative interaction between Neisseria gonorrhoeae and complement receptor 3 mediates infection of primary cervical epithelial cells. Cell Microbiol 2002; 4:571.
  93. Edwards JL. The role of complement in gonococcal infection of cervical epithelia. Vaccine 2008; 26 Suppl 8:I56.
  94. Edwards JL, Brown EJ, Ault KA, Apicella MA. The role of complement receptor 3 (CR3) in Neisseria gonorrhoeae infection of human cervical epithelia. Cell Microbiol 2001; 3:611.
  95. Edwards JL, Shao JQ, Ault KA, Apicella MA. Neisseria gonorrhoeae elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells. Infect Immun 2000; 68:5354.
  96. Merz AJ, So M. Interactions of pathogenic neisseriae with epithelial cell membranes. Annu Rev Cell Dev Biol 2000; 16:423.
  97. Chen T, Grunert F, Medina-Marino A, Gotschlich EC. Several carcinoembryonic antigens (CD66) serve as receptors for gonococcal opacity proteins. J Exp Med 1997; 185:1557.
  98. Gray-Owen SD, Dehio C, Haude A, et al. CD66 carcinoembryonic antigens mediate interactions between Opa-expressing Neisseria gonorrhoeae and human polymorphonuclear phagocytes. EMBO J 1997; 16:3435.
  99. Gray-Owen SD, Lorenzen DR, Haude A, et al. Differential Opa specificities for CD66 receptors influence tissue interactions and cellular response to Neisseria gonorrhoeae. Mol Microbiol 1997; 26:971.
  100. Simon D, Rest RF. Escherichia coli expressing a Neisseria gonorrhoeae opacity-associated outer membrane protein invade human cervical and endometrial epithelial cell lines. Proc Natl Acad Sci U S A 1992; 89:5512.
  101. Wang J, Gray-Owen SD, Knorre A, et al. Opa binding to cellular CD66 receptors mediates the transcellular traversal of Neisseria gonorrhoeae across polarized T84 epithelial cell monolayers. Mol Microbiol 1998; 30:657.
  102. Cannon JG, Buchanan TM, Sparling PF. Confirmation of association of protein I serotype of Neisseria gonorrhoeae with ability to cause disseminated infection. Infect Immun 1983; 40:816.
  103. Rechner C, Kühlewein C, Müller A, et al. Host glycoprotein Gp96 and scavenger receptor SREC interact with PorB of disseminating Neisseria gonorrhoeae in an epithelial invasion pathway. Cell Host Microbe 2007; 2:393.
  104. Gorby GL, Ehrhardt AF, Apicella MA, Elkins C. Invasion of human fallopian tube epithelium by Escherichia coli expressing combinations of a gonococcal porin, opacity-associated protein, and chimeric lipo-oligosaccharide. J Infect Dis 2001; 184:460.
  105. Rice PA. Molecular basis for serum resistance in Neisseria gonorrhoeae. Clin Microbiol Rev 1989; 2 Suppl:S112.
  106. Ingwer I, Petersen BH, Brooks G. Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae. J Lab Clin Med 1978; 92:211.
  107. Ram S, Cullinane M, Blom AM, et al. Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med 2001; 193:281.
  108. Ram S, McQuillen DP, Gulati S, et al. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 1998; 188:671.
  109. Ngampasutadol J, Tran C, Gulati S, et al. Species-specificity of Neisseria gonorrhoeae infection: do human complement regulators contribute? Vaccine 2008; 26 Suppl 8:I62.
  110. Ram S, Sharma AK, Simpson SD, et al. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 1998; 187:743.
  111. Apicella MA, Mandrell RE, Shero M, et al. Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J Infect Dis 1990; 162:506.
  112. Apicella MA, Shero M, Jarvis GA, et al. Phenotypic variation in epitope expression of the Neisseria gonorrhoeae lipooligosaccharide. Infect Immun 1987; 55:1755.
  113. Seifert HS, Wright CJ, Jerse AE, et al. Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest 1994; 93:2744.
  114. McQuillen DP, Gulati S, Ram S, et al. Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. J Infect Dis 1999; 179:124.
  115. Elkins C, Carbonetti NH, Varela VA, et al. Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated. Mol Microbiol 1992; 6:2617.
  116. Griffiss JM, Schneider H, Mandrell RE, et al. Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane. Rev Infect Dis 1988; 10 Suppl 2:S287.
  117. Mulks MH, Plaut AG. IgA protease production as a characteristic distinguishing pathogenic from harmless neisseriaceae. N Engl J Med 1978; 299:973.
  118. Hobbs MM, Sparling PF, Cohen MS, et al. Experimental Gonococcal Infection in Male Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and MS11mkC. Front Microbiol 2011; 2:123.
  119. Lin L, Ayala P, Larson J, et al. The Neisseria type 2 IgA1 protease cleaves LAMP1 and promotes survival of bacteria within epithelial cells. Mol Microbiol 1997; 24:1083.
  120. Rice PA, Vayo HE, Tam MR, Blake MS. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp Med 1986; 164:1735.
  121. Plummer FA, Chubb H, Simonsen JN, et al. Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal salpingitis. J Clin Invest 1994; 93:1748.
  122. Plummer FA, Chubb H, Simonsen JN, et al. Antibody to Rmp (outer membrane protein 3) increases susceptibility to gonococcal infection. J Clin Invest 1993; 91:339.
  123. Hedges SR, Mayo MS, Mestecky J, et al. Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun 1999; 67:3937.
  124. Hedges SR, Sibley DA, Mayo MS, et al. Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: effects of concomitant infections. J Infect Dis 1998; 178:742.
  125. Duncan JA, Gao X, Huang MT, et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009; 182:6460.
  126. Escobar A, Candia E, Reyes-Cerpa S, et al. Neisseria gonorrhoeae induces a tolerogenic phenotype in macrophages to modulate host immunity. Mediators Inflamm 2013; 2013:127017.
  127. Johnson MB, Criss AK. Neisseria gonorrhoeae phagosomes delay fusion with primary granules to enhance bacterial survival inside human neutrophils. Cell Microbiol 2013; 15:1323.
  128. Mosleh IM, Huber LA, Steinlein P, et al. Neisseria gonorrhoeae porin modulates phagosome maturation. J Biol Chem 1998; 273:35332.
  129. Zhu W, Ventevogel MS, Knilans KJ, et al. Neisseria gonorrhoeae suppresses dendritic cell-induced, antigen-dependent CD4 T cell proliferation. PLoS One 2012; 7:e41260.
  130. Boulton IC, Gray-Owen SD. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 2002; 3:229.
  131. Pantelic M, Kim YJ, Bolland S, et al. Neisseria gonorrhoeae kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-expressing human B cells and inhibits antibody production. Infect Immun 2005; 73:4171.
  132. Liu Y, Feinen B, Russell MW. New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host. Front Microbiol 2011; 2:52.
  133. Liu Y, Islam EA, Jarvis GA, et al. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms. Mucosal Immunol 2012; 5:320.
  134. Liu Y, Russell MW. Diversion of the immune response to Neisseria gonorrhoeae from Th17 to Th1/Th2 by treatment with anti-transforming growth factor β antibody generates immunological memory and protective immunity. MBio 2011; 2:e00095.
  135. Liu Y, Liu W, Russell MW. Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells. Mucosal Immunol 2014; 7:165.
  136. Liu Y, Egilmez NK, Russell MW. Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12. J Infect Dis 2013; 208:1821.